| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.074 | 0.2 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.08 | 0.2 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |